News

Article

Clinical Quiz: ACG Alcohol-Associated Liver Disease Guideline

Key Takeaways

  • ALD is a major cause of advanced hepatic disease and a frequent indication for liver transplantation, with a growing healthcare burden.
  • Advances in understanding ALD have led to significant improvements in its management and treatment.
SHOW MORE

Test your knowledge of the 2024 American College of Gastroenterology alcohol-associated liver disease guidelines with this clinical quiz!

HCPLive Clinical Quiz

HCPLive Clinical Quiz

The most common cause of advanced hepatic disease and a frequent indication for liver transplantation, the healthcare burden of alcohol-associated liver disease (ALD) has grown substantially in recent years.

It is a notable source of preventable liver-related morbidity and mortality, but advances in the understanding of ALD have facilitated significant improvements in its management and treatment. In 2024, the American College of Gastroenterology released a clinical guideline on the management of ALD to address key clinical questions specific to this patient population.

Test your knowledge of the 2024 ACG Clinical Guideline on Alcohol-Associated Liver Disease with this Clinical Quiz!

Which tool is recommended for screening patients for alcohol use disorder?


Reference

Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. The American Journal of Gastroenterology 119(1):p 30-54, January 2024. doi:10.14309/ajg.0000000000002572

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.